leisure time -WSS

leisure time

author：fashion 2025-09-29 01:35:29 - browse：81112

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： How to convince healthy people to buy insurance

WSS

Lung cancer screening guidelines updated for cigarette smokers

Health AI adoption puts security, privacy startups on investors' radar

Brain injuries and the importance of a second opinion

Baby aspirin cuts fat buildup in liver disease patients, in small study

How neuroscience research could help beat back brain cancer

Asbestos, a deadly carcinogen, banned by EPA

hotspot

leisure time

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Malaria cases in Florida and Texas: Here’s what you need to know

Gene editing the human germline: What are the risks?

After affirmative action ruling, medical educators look to 'holistic review'

Colonoscopy prep: Liquid

The high cost of giving birth even with insurance

Infant mortality in U.S. rose last year for first time in decades: CDC

Trump demands the U.S. pay no more for drugs than other countries … again

Health AI adoption puts security, privacy startups on investors' radar

leisure time

Lung cancer screening guidelines updated for cigarette smokers

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Kidney transplant patients stopped immunosuppressants in trial

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Live blog: Hearing on CRISPR

Methadone treatment changes are coming. Do they go far enough?

entertainment

leisure time

explore

hotspot